Blood and Marrow Transplant Program

Blood_Marrow_info

ucsfbenioffchildrens.org/bmt

SUPERIOR OUTCOMES FOR CHILDREN WITH RARE BLOOD DISORDERS

The Blood and Marrow Transplant Program at UCSF Benioff Children’s Hospitals is a leader in specialized treatment options for children with cancer. Our outstanding outcomes are the result of the efforts of our nationally and internationally recognized faculty, and the availability of cutting-edge clinical trials and therapies for patients with these rare disorders.

CONDITIONS TREATED

Malignant disorders
  • Acute leukemias and lymphomas
  • High-risk neuroblastomas
  • Brain tumors
  • Other rare cancers
Nonmalignant disorders
  • Inborn errors of immunity, including primary immunodeficiency diseases and primary immune regulatory disorders
  • Inborn errors of metabolism
  • Bone marrow failure syndromes (acquired and genetic)
  • Hemoglobinopathies

WHY REFER TO UCSF?

  • Personalized care plans developed for each patient, tailored to their individual condition and status
  • Cutting-edge treatments, such as gene therapy for genetic disorders, some of which are only available at UCSF Benioff Children’s Hospitals
  • Multiple clinical trials available for access to novel therapies, including ancillary trials designed to improve supportive care and outcomes
  • A unique multidisciplinary forum designed to optimize outcomes for immunocompromised critical care patients who require intensive support
  • Multidisciplinary clinics for inborn errors of metabolism and chronic graft versus host disease
  • Access to the Stad Center for Pediatric Pain, Palliative & Integrative Medicine, dedicated to relieving pain and improving quality of life for hospitalized children
  • Clinical social workers provide emotional support and resource coordination for the whole family, including assistance with transportation and local lodging
  • Child life specialists and creative arts therapists who develop positive health care experiences for hospitalized children and their families
  • Availability of CAR T-cell and other novel immunotherapies, including first commercially available products from Novartis (Kymriah) and Kite (Yescarta)

 

INFORMATION / REFERRALS

  • PHONE(415) 476-2188
  • FAX(415) 502-4867

OUR TEAM

Christopher Dvorak, MD
Pediatric hematologist-oncologist
Chief, Division of Pediatric Allergy, Immunology, and BMT
Director, Pediatric Cellular Therapy Laboratory

Sandhya Kharbanda, MD
Pediatric hematologist-oncologist
Medical Director, Pediatric BMT Program, San Francisco

Julia Chu, MD, MPH
Pediatric hematologist-oncologist

ADVERTISEMENT

Morton Cowan, MD
Pediatric immunologist

Jasmeen Dara, MD, MS
Pediatric immunologist

Michelle Hermiston, MD, PhD
Pediatric hematologist-oncologist
Director, Immunotherapy Program

Christine Higham, MD
Pediatric hematologist-oncologist

James Huang, MD
Pediatric hematologist-oncologist
Director, Pediatric Hematology

Janel Long-Boyle, PharmD, PhD
Pharmacotherapist

Alexis Melton, MD, PhD
Pediatric hematologist-oncologist
Director of Apheresis, San Francisco

Gabriel Salinas Cisneros, MD
Pediatric hematologist-oncologist

Kristin Shimano, MD
Pediatric hematologist-oncologist

Lena Winestone, MD, MS
Pediatric hematologist-oncologist

Matt Zinter, MD
Pediatric critical care specialist

Print Document